A detailed history of Geode Capital Management, LLC transactions in Vigil Neuroscience, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 226,083 shares of VIGL stock, worth $384,341. This represents 0.0% of its overall portfolio holdings.

Number of Shares
226,083
Previous 159,371 41.86%
Holding current value
$384,341
Previous $637,000 20.57%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.92 - $4.65 $194,799 - $310,210
66,712 Added 41.86%
226,083 $768,000
Q2 2024

Aug 09, 2024

SELL
$2.51 - $4.66 $438,926 - $814,898
-174,871 Reduced 52.32%
159,371 $637,000
Q1 2024

May 13, 2024

BUY
$2.68 - $3.63 $50,126 - $67,895
18,704 Added 5.93%
334,242 $1.14 Million
Q4 2023

Feb 13, 2024

BUY
$2.97 - $8.6 $30,778 - $89,121
10,363 Added 3.4%
315,538 $1.07 Million
Q3 2023

Nov 13, 2023

BUY
$4.8 - $9.92 $97,593 - $201,693
20,332 Added 7.14%
305,175 $1.64 Million
Q2 2023

Aug 11, 2023

BUY
$8.11 - $10.54 $1.4 Million - $1.82 Million
172,451 Added 153.44%
284,843 $2.68 Million
Q1 2023

May 15, 2023

BUY
$8.77 - $12.7 $75,641 - $109,537
8,625 Added 8.31%
112,392 $1.1 Million
Q4 2022

Feb 13, 2023

BUY
$8.74 - $15.99 $279,225 - $510,848
31,948 Added 44.48%
103,767 $1.3 Million
Q3 2022

Nov 14, 2022

BUY
$2.37 - $9.61 $28,852 - $116,992
12,174 Added 20.41%
71,819 $653,000
Q2 2022

Aug 12, 2022

SELL
$2.23 - $7.81 $83,480 - $292,367
-37,435 Reduced 38.56%
59,645 $153,000
Q1 2022

May 13, 2022

BUY
$7.03 - $17.29 $682,472 - $1.68 Million
97,080 New
97,080 $682,000

Others Institutions Holding VIGL

About Vigil Neuroscience, Inc.


  • Ticker VIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,268,600
  • Market Cap $48.1M
  • Description
  • Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...
More about VIGL
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.